Obesity
News from the FDA/CDC
Compounded Semaglutide Overdoses Tied to Hospitalizations
Compounded semaglutide products may differ from approved products in ways that contribute to potential errors.
Commentary
Which GI Side Effects Should GLP-1 Prescribers Worry About?
Given the various favorable hepatic effects of GLP-1 RAs, it is likely that the composite benefit on MASLD is multifactorial.
Perspectives
GLP-1 Receptor Agonists in Endoscopy
In this issue of Perspectives, experts debate the cessation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) prior to endoscopy.
Conference Coverage
Semaglutide Aids Weight Loss With or Without Bariatric Surgery
In a comparison of people who had weight loss surgery with those who had not, total weight loss was almost identical: 5.8% in those who had...
Conference Coverage
GI Complications With GLP-1s for Weight Loss: Reexamining the Risks
The researchers found no significant association between GLP-1s and acute pancreatitis.
Conference Coverage
Genetic Test Can Predict Response to Semaglutide for Weight Loss
Further prospective studies are needed to assess the validity of the test in a more diverse population and with different weight loss...
Conference Coverage
Endoscopic Procedure Targets ‘Hunger Hormone’ for Weight Loss
Researchers targeted the gastric fundus because its mucosal lining contains 80%-90% of the cells that produce ghrelin.
Latest News
Semaglutide Curbs MASLD Severity in People Living With HIV
Most participants lost significant weight and weight loss was closely associated with improvements in MASLD.
Latest News
Does Bariatric Surgery Increase or Decrease Cancer Risk? It Depends.
Bariatric surgery is related to decreased risk for hormone-related cancers but may increase colorectal cancer, although the data are mixed.
From the Journals
Ozempic is Appealing, but Not Cost-Effective, for Obesity Treatment
Surgical and endoscopic options to treat obesity are cost effective, but not the pharmacological intervention semaglutide.